In addition, m6A regulators are highly expressed in AML and are related to patient survival as well as relapse rates, indicating that m6A regulators can serve as promising biomarkers for diagnosis, prognostic prediction and therapeutic response evaluation in AML patients. This evidence concerns the gene METTL3 and acute myeloid leukemia.